Sagimet Biosciences (SGMT) Gains from Investment Securities (2022 - 2023)
Sagimet Biosciences' (SGMT) quarterly Gains from Investment Securities came in at -$5000.0 in Q4 2023, down 25.0% quarter-over-quarter from -$4000.0 in Q3 2023.
Sagimet Biosciences (SGMT) Gains from Investment Securities (2022 - 2023) Analysis & Trends
Sagimet Biosciences' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$5000.0 for Q4 2023.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to -$5000.0 in Q4 2023; TTM through Dec 2023 was -$8000.0, a N/A change from a year earlier, with the FY2023 full-year figure at -$4000.0, down 33.33% from the prior year.
- Gains from Investment Securities fell to -$5000.0 in Q4 2023 per SGMT's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2000.0 in Q1 2023 and bottomed at -$5000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn |
| 10 | Sagimet Biosciences | 240.62 Mn | 240.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -5,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |